AU3434601A - Compositions and methods for the treatment of immune related diseases - Google Patents
Compositions and methods for the treatment of immune related diseasesInfo
- Publication number
- AU3434601A AU3434601A AU34346/01A AU3434601A AU3434601A AU 3434601 A AU3434601 A AU 3434601A AU 34346/01 A AU34346/01 A AU 34346/01A AU 3434601 A AU3434601 A AU 3434601A AU 3434601 A AU3434601 A AU 3434601A
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- treatment
- methods
- related diseases
- immune related
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1999/028313 WO2000032221A2 (en) | 1998-12-01 | 1999-11-30 | Promotion or inhibition of angiogenesis and cardiovascularization |
WOUS99/28313 | 1999-11-30 | ||
US17026299P | 1999-12-09 | 1999-12-09 | |
US60170262 | 1999-12-09 | ||
US17205999P | 1999-12-23 | 1999-12-23 | |
US60172059 | 1999-12-23 | ||
US17548100P | 2000-01-11 | 2000-01-11 | |
US60175481 | 2000-01-11 | ||
US17711800P | 2000-01-20 | 2000-01-20 | |
US60177118 | 2000-01-20 | ||
WOUS00/04342 | 2000-02-18 | ||
PCT/US2000/004342 WO2000078961A1 (en) | 1999-06-23 | 2000-02-18 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US18720200P | 2000-03-03 | 2000-03-03 | |
US60187202 | 2000-03-03 | ||
PCT/US2000/014941 WO2000073348A2 (en) | 1999-06-02 | 2000-05-30 | Methods and compositions for inhibiting neoplastic cell growth |
WOUS00/14941 | 2000-05-30 | ||
US20983200P | 2000-06-05 | 2000-06-05 | |
US60209832 | 2000-06-05 | ||
WOUS00/23328 | 2000-08-24 | ||
PCT/US2000/023328 WO2001016318A2 (en) | 1999-09-01 | 2000-08-24 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US60000000 | 2000-09-15 | ||
PCT/US2000/030873 WO2001040465A2 (en) | 1999-11-30 | 2000-11-10 | Compositions and methods for the treatment of immune related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3434601A true AU3434601A (en) | 2001-06-12 |
Family
ID=27558595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU34346/01A Abandoned AU3434601A (en) | 1999-11-30 | 2000-11-10 | Compositions and methods for the treatment of immune related diseases |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1234036A2 (en) |
JP (4) | JP4211966B2 (en) |
AU (1) | AU3434601A (en) |
CA (1) | CA2390786A1 (en) |
WO (1) | WO2001040465A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6503730B1 (en) | 1997-06-19 | 2003-01-07 | Schering Corporation | Nucleic acids encoding a cysteine rich protein |
US7365157B2 (en) * | 1999-12-23 | 2008-04-29 | Genentech, Inc. | PRO9912 polypeptides |
EP1897946B1 (en) * | 1999-12-23 | 2012-07-11 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US7164001B2 (en) | 2000-01-20 | 2007-01-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
AU2002335054A1 (en) * | 2001-12-19 | 2003-07-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CA2518101A1 (en) * | 2003-03-03 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the treatment of systemic lupus erythematosis |
JP2007518404A (en) * | 2003-12-16 | 2007-07-12 | ジェネンテック・インコーポレーテッド | Novel gene disruption, compositions and methods relating thereto |
CA2721713C (en) | 2008-05-05 | 2019-07-09 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
EP2427203B1 (en) | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6066322A (en) * | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
US5874230A (en) * | 1996-07-10 | 1999-02-23 | Tularik, Inc. | Assays using TRAF2-associated protein kinase polypeptides |
AU4268097A (en) * | 1996-09-12 | 1998-04-02 | Human Genome Sciences, Inc. | Chemokine alpha-4 |
EP0958366A1 (en) * | 1996-12-05 | 1999-11-24 | Human Genome Sciences, Inc. | Human chemokine beta-13 |
AU6891098A (en) * | 1997-04-10 | 1998-10-30 | Genetics Institute Inc. | Secreted expressed sequence tags (sests) |
WO1998058061A1 (en) * | 1997-06-19 | 1998-12-23 | Schering Corporation | Mammalian genes; related reagents |
WO1999038959A1 (en) * | 1998-01-30 | 1999-08-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
EP1071772A2 (en) * | 1998-04-24 | 2001-01-31 | Genentech, Inc. | Fizz proteins |
-
2000
- 2000-11-10 CA CA002390786A patent/CA2390786A1/en not_active Abandoned
- 2000-11-10 AU AU34346/01A patent/AU3434601A/en not_active Abandoned
- 2000-11-10 WO PCT/US2000/030873 patent/WO2001040465A2/en active Search and Examination
- 2000-11-10 EP EP00991686A patent/EP1234036A2/en not_active Withdrawn
- 2000-11-10 JP JP2001542530A patent/JP4211966B2/en not_active Expired - Lifetime
-
2005
- 2005-08-15 JP JP2005235351A patent/JP4242371B2/en not_active Expired - Fee Related
-
2006
- 2006-01-20 JP JP2006013034A patent/JP4226605B2/en not_active Expired - Lifetime
-
2008
- 2008-04-16 JP JP2008107191A patent/JP2008301810A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1234036A2 (en) | 2002-08-28 |
JP4242371B2 (en) | 2009-03-25 |
WO2001040465A2 (en) | 2001-06-07 |
JP2008301810A (en) | 2008-12-18 |
WO2001040465A3 (en) | 2002-03-21 |
JP2006068007A (en) | 2006-03-16 |
JP4226605B2 (en) | 2009-02-18 |
JP2006197937A (en) | 2006-08-03 |
JP4211966B2 (en) | 2009-01-21 |
JP2003530082A (en) | 2003-10-14 |
CA2390786A1 (en) | 2001-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7722600A (en) | Compositions and methods for the diagnosis and treatment of immune disorders | |
WO2003072035A8 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004041170A9 (en) | Compositions and methods for the treatment of immune related diseases | |
IL145470A0 (en) | Compositions for the treatment of immune diseases | |
WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
AU2495200A (en) | Compositions and methods for the treatment of tumor | |
AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
AU4205100A (en) | Methods and compositions for the treatment of pancreatitis | |
EP1572116A4 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1576137A4 (en) | Compositions and methods for the treatment of immune related diseases | |
AU2212299A (en) | Compositions and methods for the treatment of tumor | |
AU7748000A (en) | Method and composition for the treatment of dermatologic diseases | |
KR100510795B1 (en) | Compositions and Methods for the Treatment of Tumor | |
AU3632600A (en) | Compositions and methods for the treatment of immune related diseases | |
AU4340700A (en) | Methods and compositions for use in the treatment of hyperlipidemia | |
AUPQ415899A0 (en) | Compositions for and methods of treatment of allergic diseases | |
AU5309600A (en) | Compositions and methods for the treatment and diagnosis of immune disorders | |
AU9395998A (en) | Compositions and methods for the treatment of immune related diseases | |
HUP0104963A3 (en) | Compositions for the treatment of skin diseases | |
AU3434601A (en) | Compositions and methods for the treatment of immune related diseases | |
AU4511201A (en) | Compositions and methods for the induction and treatment of retinal detachments | |
WO2004024076A8 (en) | Novel compositions and methods for the treatment of immune related diseases | |
AU1953701A (en) | Methods and compositions for treatment of inflammatory disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |